Skip to main content
OpenTrials
Completed

NCT Number: NCT02704468

FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients

Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness. The cardio-ankle vascular index (CAVI) is a new index of overall stiffness and can estimated the risk of atherosclerosis.

Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vascular Stiffness

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bangkok metropolitan administraiton of vajira hospital

Bangkok, 10170, Thailand

About this study

A total of 90 participants who underwent renal transplant were included in the study. The following measures were done and laboratory data were collected. CAVI, Ecchocariogram, Homocysteine, Hs-CRP, Carotid IMT, FGF-21, Medication after renal transplantation, incidence of cardiovascular disease correlation between categorical data was done by using Pearson's correlation test and multiple regression analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • renal transplant patients patients for more than 1 month

Exclusion criteria

  • who had contraindication for CAVI
  • current smoker
  • eGFR <15 ml/min/173
  • cardiac arrthymia

Treatment and study plan

CAVI and FGF-21

Other

FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness

Primary outcomes

  1. association between CAVI and FGF-21 with arterial stiffness in renal transplant patients

    Time frame: 1 month

    cross sectional study

Secondary outcomes

  1. association between Hs-CRP,Homocystein with CAVI

    Time frame: 1 month

    cross sectional study

Sponsors and collaborators

Lead sponsor

Bangkok Metropolitan Administration Medical College and Vajira Hospital

Other Gov

Registry information

Acronym: CAVIFGF21

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Mar 10, 2016
Registry last updated
Jul 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.